Long-term follow-up of a randomized post-induction therapy trial in acute myelogenous leukemia (a Southeastern Cancer Study Group trial)

A phase III clinical trial was designed to determine if more intensive induction and consolidation therapy for acute myeloblastic leukemia increases the remission rate and prolongs survival. A minor objective was to determine if the use of non-cross resistant drugs was more effective than the same drugs used for induction. Patients with untreated leukemia between the ages of 15 and 50 were given daunorubicin 45 mg/m2 for the first 3 days of a 10-day continuous infusion of cytosine arabinoside, initially at a dose of 2000 mg/m2 but reduced to 100 mg/m2 because of toxicity. Those under 36 achieving a complete remission and with an histocompatible donor were assigned to a transplant arm. The rest were randomized to receive one of three consolidation arms: A, cytosine arabinoside, 200 mg/m2 daily for 7 days and daunorubicin 45 mg/m2 daily for 3 days for three courses; B, one course as in Arm A followed by amsacrine, 120 mg/m2 daily for 5 days followed by a 5-day continuous infusion of azacytidine, 150 mg/m2/day; C, thioguanine and cytosine arabinoside, 100 mg/m2 every 12 h and daunorubicin 10 mg/m2 daily for 5 days for three courses followed by four maintenance courses of cytosine arabinoside, 100 mg/m2 daily for 5 days and daunorubicin, 45 mg/m2 for 2 days every 13 weeks. From 1981 to 1986, 398 eligible patients were enrolled and 219 achieved a complete remission. The initial induction dose of cytosine arabinoside was reduced after five of 29 patients exhibited fatal gastrointestinal toxicity. Only 11 patients were assigned to the transplant arm. There were no significant differences in the consolidation arms. The 5 year disease-free survivals were 38, 31 and 27% in arms A, B, and C respectively. Intensive consolidation therapy with the same or different drugs used in induction was as effective as lower dose consolidation followed by maintenance therapy.     

孤岛油田西区聚合物驱开发研究

孤岛油田西区注聚区1997年3月投入注聚后，高渗层得到有效封堵，吸水剖面得到明显改善。注聚期间，通过实施注聚区外围水井降水或停注、油井放大生产压差和调整注聚井注入速度等开发措施，扩大了聚合物波及体积，聚合物驱取得了明显效果。     

HPMBP与伯胺N_(1923)对希土元素(Ⅲ)的协同萃取

本文研究了HPMBP与伯胺N_(1923)的二甲苯溶液,从盐酸介质中协同萃取希土(Ⅲ)的机理。用斜率法、恒摩尔法确定了协萃配合物的组成为:RNH_3Ln(PMBP)_4。求得关于Pr(Ⅲ)协萃反应的平衡常数及协萃配合物的生成常数分别为:logK_(12)=-1.95;logβ_(12)=3.94。实验发现,协萃系数(R)随希土元素的原子序数(Z)递变而呈现“双峰效应”。还研究了协萃配合物的IR,NMR谱。     

中条山供水工程取水首部电气设计的特点

对70m落差下大型泵站供电设计中电缆的受发热这两个难点进行了论述，并通过应用特种电缆和工程塑料解决了这些难题，使泵站的设计能够较好地满足安全、便利运行的要求，为地质条件较为复杂的情况下设计泵站提供了一个比较理想的模式。     

硼酸铝晶须增强环氧树脂和双马来酰亚胺树脂体系的研究

本文以硼酸铝晶须为增强剂，以4，5-环氧环己烷-1，2-二甲酸二缩水甘油酯(TDE-85)，甲基纳狄克酸酐(MNA)、N，N’-二胺基二苯甲烷型双马来酰亚胺(BMI)/O，O′-二烯丙基双酚A(BA)体系分别作为基体制备晶须增强复合材料。研究了晶须对树脂的尺寸、表面处理方法、含量对树脂体系力学性能和热性能的影响；通过扫描电子显微镜(SEM)分析了浇注体的弯曲、冲击断口，研究晶须的增强机理。     

The new structure of fibre glass reinforced plastics bolt

The develop actuality and direction of FRP (fibre glass reinforced plastics) bolt in the world are analyzed. The new type structure of FRP bolt was designed. Trial data indicate that, all kinds of capability target of this FRP bolt all achieve and exceed the country stand-ard, substitute present metal bolt, wood bolt and bamboo bolt and other side bolt, it can gain magnitude technology and economy benefit. FRP bolt mechanization product line produce ef-ficiency is high, its throughput a day are 750 base, this can meet demand of hit-small mining company.